Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2019 08:00 ET | Source: MediWound Ltd.

MediWound to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 13

YAVNE, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
July 22, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Launches EscharEx® U.S. Clinical Development Program

Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host...
July 16, 2019 08:00 ET | Source: MediWound Ltd.

MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds

YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
June 11, 2019 07:30 ET | Source: MediWound Ltd.

MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer

YAVNE, Israel, June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
June 04, 2019 07:30 ET | Source: MediWound Ltd.

NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health

YAVNE, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
May 29, 2019 07:30 ET | Source: MediWound Ltd.

BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn

Total non-dilutive funds for NexoBrid now valued at up to $196 Million MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use...
May 21, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Reports First Quarter 2019 Financial Results

Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel for Commercial Rights...
May 14, 2019 08:00 ET | Source: MediWound Ltd.

MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time

YAVNE, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
May 07, 2019 02:00 ET | Source: MediWound Ltd.

MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America

$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License...
March 26, 2019 08:00 ET | Source: MediWound Ltd.

MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018

YAVNE, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...